Background: Choline and betaine intakes have been related to
cardiovascular health.
Objectives: We aimed to explore the relation between 1-y changes
in dietary intake of choline or betaine and 1-y changes in
cardiometabolic and renal function traits within the frame of the
PREDIMED (PREvención con DIeta MEDiterránea)-Plus trial.
Methods: We used baseline and 1-y follow-up data from 5613
participants (48.2% female and 51.8% male; mean ± SD age:
65.01 ± 4.91 y) to assess cardiometabolic traits, and 3367
participants to assess renal function, of the Spanish PREDIMEDPlus
trial. Participants met ≥3 criteria of metabolic syndrome and
had overweight or obesity [BMI (in kg/m2) ≥27 and ≤40]. These
criteria were similar to those of the PREDIMED parent study.
Dietary intakes of choline and betaine were estimated from the
FFQ.
Results: The greatest 1-y increase in dietary choline or betaine
intake (quartile 4) was associated with improved serum glucose
concentrations (−3.39 and −2.72 mg/dL for choline and betaine,
respectively) and HbA1c levels (−0.10% for quartile 4 of either
choline or betaine intake increase). Other significant changes
associated with the greatest increase in choline or betaine intake
were reduced body weight (−2.93 and −2.78 kg, respectively), BMI
(−1.05 and −0.99, respectively), waist circumference (−3.37 and
−3.26 cm, respectively), total cholesterol (−4.74 and −4.52 mg/dL,
respectively), and LDL cholesterol (−4.30 and −4.16 mg/dL,
respectively). Urine creatinine was reduced in quartile 4 of 1-y
increase in choline or betaine intake (−5.42 and −5.74 mg/dL,
respectively).
Conclusions: Increases in dietary choline or betaine intakes
were longitudinally related to improvements in cardiometabolic
parameters. Markers of renal function were also slightly improved,
and they require further investigation. This trial was registered at
https://www.isrctn.com/ as ISRCTN89898870. Am J Clin Nutr
2022;116:1565–1579.